Results 161 to 170 of about 2,637,757 (313)

Ninth Flyer 17_2_2007

open access: yes, 2014
The quarterly newsletter, The Ninth Flyer, published by the Ninth Air Force Association, Inc.
9th Air Force Association
core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Ninth Flyer 10_3_2000

open access: yes, 2014
The quarterly newsletter, The Ninth Flyer, published by the Ninth Air Force Association, Inc.
9th Air Force Association
core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

Ninth Flyer 9_1_1999

open access: yes, 2014
The quarterly newsletter, The Ninth Flyer, published by the Ninth Air Force Association, Inc.
9th Air Force Association
core  

Analysis of Bond Strength of Bioceramic Sealer Following Irrigation with Chlorhexidine. [PDF]

open access: yesIran Endod J
Costa LG   +5 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Ninth Flyer 7_2_1997

open access: yes, 2014
The quarterly newsletter, The Ninth Flyer, published by the Ninth Air Force Association, Inc.
9th Air Force Association
core  

Towards an Integrated Staging Model for Bipolar Disorders: An International Society for Bipolar Disorders (ISBD) Staging Task Force Consensus Report. [PDF]

open access: yesBipolar Disord
Kupka R   +27 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

open access: yesMolecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy